Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

$53.74 -0.41 (-0.76 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$54.15
Today's Range$54.13 - $53.14
52-Week Range$37.26 - $65.51
Volume680,938 shs
Average Volume1.49 million shs
Market Capitalization$6.68 billion
P/E Ratio361
Dividend YieldN/A
Beta2.89

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:IONS
  • CUSIP: 46433010
  • Web: www.ionispharma.com
Debt:
  • Debt-to-Equity Ratio: 1.50%
  • Current Ratio: 6.25%
  • Quick Ratio: 6.21%
Price-To-Earnings:
  • Trailing P/E Ratio: 361
  • Forward P/E Ratio: -895.67
Sales & Book Value:
  • Annual Sales: $346.62 million
  • Price / Sales: 19.35
  • Book Value: $0.82 per share
  • Price / Book: 65.54
Profitability:
  • Trailing EPS: $0.14
  • Net Income: ($86,550,000.00)
  • Net Margins: 3.46%
  • Return on Equity: 7.50%
  • Return on Assets: 1.58%
Misc:
  • Employees: 435
  • Outstanding Shares: 124,800,000
 

Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its earnings results on Tuesday, August, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.52) by $0.05. The company had revenue of $38.50 million for the quarter, compared to analyst estimates of $38.52 million. Ionis Pharmaceuticals had a net margin of 3.46% and a return on equity of 7.50%. The firm's revenue for the quarter was down 68.0% on a year-over-year basis. View Ionis Pharmaceuticals' Earnings History.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

14 Wall Street analysts have issued 1-year target prices for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $65.00. On average, they expect Ionis Pharmaceuticals' share price to reach $50.38 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.

What are Wall Street analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (11/9/2017)
  • 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:

  • Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 72)
  • Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance (Age 55)
  • B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director (Age 63)
  • Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary (Age 43)
  • C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research (Age 60)
  • Richard S. Geary Ph.D., Senior Vice President - Development (Age 59)
  • Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development (Age 55)
  • Sarah Boyce, Chief Business Officer (Age 45)
  • Spencer R. Berthelsen M.D., Independent Director (Age 64)
  • Breaux B. Castleman, Independent Director (Age 76)

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.60%), Pinnacle Associates Ltd. (1.12%), Wells Fargo & Company MN (0.92%), American Century Companies Inc. (0.92%), First Trust Advisors LP (0.79%) and Tocqueville Asset Management L.P. (0.57%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Pinnacle Associates Ltd., Smith Asset Management Group LP, Los Angeles Capital Management & Equity Research Inc., Canada Pension Plan Investment Board, California State Teachers Retirement System, Tocqueville Asset Management L.P. and Tanaka Capital Management Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., First Trust Advisors LP, Frontier Capital Management Co. LLC, JPMorgan Chase & Co., Asymmetry Capital Management L.P., Crestline Management LP, Axon Capital LP and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $53.74.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $6.68 billion and generates $346.62 million in revenue each year. The company earns ($86,550,000.00) in net income (profit) each year or $0.14 on an earnings per share basis. Ionis Pharmaceuticals employs 435 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 Gazelle Ct, CARLSBAD, CA 92010-6670, United States. The company can be reached via phone at +1-760-9319200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  378 (Vote Outperform)
Underperform Votes:  391 (Vote Underperform)
Total Votes:  769
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ionis Pharmaceuticals (NASDAQ:IONS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $50.38 (6.24% downside)

Consensus Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$64.00 -> $65.00N/AView Rating Details
11/8/2017Morgan StanleyBoost Price TargetEqual Weight$45.00 -> $49.00N/AView Rating Details
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingHold$50.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell -> Sell$30.00N/AView Rating Details
9/21/2017Barclays PLCLower Price TargetEqual Weight$55.00 -> $52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$65.00LowView Rating Details
8/14/2017LaidlawReiterated RatingBuy$65.00LowView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingUnderperform$17.00 -> $18.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$57.00HighView Rating Details
5/22/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Ionis Pharmaceuticals (NASDAQ:IONS)

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.06)($0.09)$93.29 million$104.15 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
2017 EPS Consensus Estimate: $0.07
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)$0.16$0.05
Q2 20172($0.38)$0.19($0.10)
Q3 20172$0.07$0.07$0.07
Q4 20172($0.09)$0.17$0.04
Q1 20182($0.28)($0.04)($0.16)
Q2 20182($0.29)($0.03)($0.16)
Q3 20182($0.27)$0.00($0.14)
Q4 20182($0.25)$0.05($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ IONS)

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 90.22%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Elizabeth L HougenSVPSell7,000$54.35$380,450.00View SEC Filing  
11/15/2017Joseph Klein IIIDirectorSell2,250$53.56$120,510.00View SEC Filing  
11/13/2017Joseph Klein IIIDirectorSell3,000$55.39$166,170.00View SEC Filing  
11/1/2017Patrick R O'neilSVPSell1,000$58.35$58,350.00View SEC Filing  
10/18/2017B Lynne ParshallCOOSell16,118$65.00$1,047,670.00View SEC Filing  
10/18/2017C Frank BennettSVPSell12,250$65.00$796,250.00View SEC Filing  
10/13/2017Richard S GearySVPSell8,268$60.00$496,080.00View SEC Filing  
10/13/2017Stanley T CrookeChairmanSell16,500$59.46$981,090.00View SEC Filing  
10/5/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
10/4/2017Stanley T CrookeChairmanSell27,500$52.89$1,454,475.00View SEC Filing  
10/2/2017Stanley T CrookeCEOSell15,000$52.00$780,000.00View SEC Filing  
9/6/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.00View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.00View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.00View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.00View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.15View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.00View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.00View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.50View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.00View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.00View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.00View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.00View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.00View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.00View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.50View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.00View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ionis Pharmaceuticals (NASDAQ IONS)

Source:
DateHeadline
Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to JanssenIonis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
finance.yahoo.com - November 18 at 2:24 AM
Ionis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 2,250 SharesIonis Pharmaceuticals, Inc. (IONS) Director Joseph Klein III Sells 2,250 Shares
www.americanbankingnews.com - November 17 at 8:56 PM
Ionis Pharmaceuticals, Inc. (IONS) SVP Elizabeth L. Hougen Sells 7,000 SharesIonis Pharmaceuticals, Inc. (IONS) SVP Elizabeth L. Hougen Sells 7,000 Shares
www.americanbankingnews.com - November 17 at 8:37 PM
Ionis Pharma (IONS) Agrees to License Second Orally Delivered ... - StreetInsider.comIonis Pharma (IONS) Agrees to License Second Orally Delivered ... - StreetInsider.com
www.streetinsider.com - November 17 at 7:24 AM
Joseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) StockJoseph Klein III Sells 3,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - November 14 at 8:26 PM
Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias - GlobeNewswire (press release)Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias - GlobeNewswire (press release)
globenewswire.com - November 14 at 3:12 AM
Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare HyperlipidemiasAkcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias
finance.yahoo.com - November 13 at 4:47 PM
Ionis Pharmaceuticals (IONS) CEO Dr. Stan Crooke on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaIonis Pharmaceuticals' (IONS) CEO Dr. Stan Crooke on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 13 at 6:56 AM
Ionis Pharmaceuticals' Earnings Results Fuel VolatilityIonis Pharmaceuticals' Earnings Results Fuel Volatility
finance.yahoo.com - November 12 at 10:49 AM
Ionis Pharmaceuticals, Inc. (IONS) Expected to Announce Quarterly Sales of $116.22 MillionIonis Pharmaceuticals, Inc. (IONS) Expected to Announce Quarterly Sales of $116.22 Million
www.americanbankingnews.com - November 12 at 3:08 AM
Ionis Pharma (IONS) Announces Dynacure has Licensed Dyn101 - StreetInsider.comIonis Pharma (IONS) Announces Dynacure has Licensed Dyn101 - StreetInsider.com
www.streetinsider.com - November 11 at 12:40 PM
 Brokerages Expect Ionis Pharmaceuticals, Inc. (IONS) Will Post Earnings of -$0.08 Per Share Brokerages Expect Ionis Pharmaceuticals, Inc. (IONS) Will Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - November 10 at 9:08 PM
FY2017 Earnings Forecast for Ionis Pharmaceuticals, Inc. Issued By Leerink Swann (IONS)FY2017 Earnings Forecast for Ionis Pharmaceuticals, Inc. Issued By Leerink Swann (IONS)
www.americanbankingnews.com - November 10 at 2:42 PM
Ionis Pharmaceuticals, Inc. (IONS) Downgraded by Zacks Investment ResearchIonis Pharmaceuticals, Inc. (IONS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 10 at 12:22 AM
Brokers Issue Forecasts for Ionis Pharmaceuticals, Inc.s FY2017 Earnings (IONS)Brokers Issue Forecasts for Ionis Pharmaceuticals, Inc.'s FY2017 Earnings (IONS)
www.americanbankingnews.com - November 9 at 7:36 AM
Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : November 8, 2017Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : November 8, 2017
finance.yahoo.com - November 9 at 6:52 AM
Edited Transcript of IONS earnings conference call or presentation 7-Nov-17 4:30pm GMTEdited Transcript of IONS earnings conference call or presentation 7-Nov-17 4:30pm GMT
finance.yahoo.com - November 8 at 2:46 AM
Pro-Trader Daily: Corporate News Blog - Ionis Submits Marketing Authorization Application to EMA for InotersenPro-Trader Daily: Corporate News Blog - Ionis Submits Marketing Authorization Application to EMA for Inotersen
www.finanznachrichten.de - November 7 at 4:43 PM
Ionis Pharma (IONS) Names Brett Monia as COOIonis Pharma (IONS) Names Brett Monia as COO
www.streetinsider.com - November 7 at 4:43 PM
Corporate News Blog - Ionis Submits Marketing Authorization Application to EMA for InotersenCorporate News Blog - Ionis Submits Marketing Authorization Application to EMA for Inotersen
finance.yahoo.com - November 7 at 4:42 PM
Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017
finance.yahoo.com - November 7 at 4:42 PM
Ionis Announces Management TransitionsIonis Announces Management Transitions
finance.yahoo.com - November 7 at 4:42 PM
Ionis Pharmaceuticals misses Street 3Q forecastsIonis Pharmaceuticals misses Street 3Q forecasts
finance.yahoo.com - November 7 at 4:42 PM
Ionis (IONS) Beats on Q3 Earnings, Revenues MissIonis (IONS) Beats on Q3 Earnings, Revenues Miss
finance.yahoo.com - November 7 at 4:42 PM
Ionis Pharmaceuticals, Inc. to Host Earnings CallIonis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 4:42 PM
Ionis Shares Dip After Third-Quarter Sales, Earnings MissIonis Shares Dip After Third-Quarter Sales, Earnings Miss
finance.yahoo.com - November 7 at 4:42 PM
Should You Buy Ionis (IONS) Ahead of Earnings? - NasdaqShould You Buy Ionis (IONS) Ahead of Earnings? - Nasdaq
www.nasdaq.com - November 7 at 4:45 AM
Ionis Pharma (IONS) Announces Submission of NDA for Inotersen - StreetInsider.comIonis Pharma (IONS) Announces Submission of NDA for Inotersen - StreetInsider.com
www.streetinsider.com - November 7 at 4:45 AM
Should You Buy Ionis (IONS) Ahead of Earnings?Should You Buy Ionis (IONS) Ahead of Earnings?
finance.yahoo.com - November 7 at 4:45 AM
Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDAIonis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA
finance.yahoo.com - November 7 at 4:45 AM
Head to Head Review: Ionis Pharmaceuticals (IONS) & Its RivalsHead to Head Review: Ionis Pharmaceuticals (IONS) & Its Rivals
www.americanbankingnews.com - November 6 at 5:22 AM
Heres Why Alnylams Gain Is Ionis Pharmaceuticals Loss Today - Motley FoolHere's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today - Motley Fool
www.fool.com - November 4 at 2:39 AM
Ionis Pharma (IONS) Submission of MAA for Inotersen to EMA - StreetInsider.comIonis Pharma (IONS) Submission of MAA for Inotersen to EMA - StreetInsider.com
www.streetinsider.com - November 4 at 2:39 AM
Ionis Pharmaceuticals, Inc. (IONS) SVP Patrick R. Oneil Sells 1,000 SharesIonis Pharmaceuticals, Inc. (IONS) SVP Patrick R. O'neil Sells 1,000 Shares
www.americanbankingnews.com - November 3 at 9:25 PM
Ionis Pharma (IONS) Submission of MAA for Inotersen to EMAIonis Pharma (IONS) Submission of MAA for Inotersen to EMA
www.streetinsider.com - November 3 at 10:18 AM
Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis MeetingIonis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting
finance.yahoo.com - November 3 at 10:18 AM
Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines AgencyIonis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency
finance.yahoo.com - November 3 at 10:18 AM
Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ...Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ...
www.prnewswire.com - November 2 at 2:35 AM
Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis MeetingIonis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting
finance.yahoo.com - November 2 at 2:35 AM
Ionis Pharmaceuticals, Inc. (IONS) Given Average Recommendation of "Hold" by BrokeragesIonis Pharmaceuticals, Inc. (IONS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 1 at 2:16 PM
AZN Gets Speedy Nod, RBP-6000 Just One Step Away From Approval, STML Soars - NasdaqAZN Gets Speedy Nod, RBP-6000 Just One Step Away From Approval, STML Soars - Nasdaq
www.nasdaq.com - November 1 at 4:28 AM
Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx - NasdaqAkcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx - Nasdaq
www.nasdaq.com - October 31 at 11:25 PM
Ionis Pharmaceuticals, Inc. (IONS) Set to Announce Earnings on TuesdayIonis Pharmaceuticals, Inc. (IONS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with ... - PR Newswire (press release)Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with ... - PR Newswire (press release)
www.prnewswire.com - October 29 at 2:54 AM
Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.
finance.yahoo.com - October 28 at 7:06 AM
Ionis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZAIonis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZA
finance.yahoo.com - October 28 at 7:06 AM
Ionis Pharmaceuticals, Inc. (IONS) Stock Rating Upgraded by Zacks Investment ResearchIonis Pharmaceuticals, Inc. (IONS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 28 at 12:26 AM
Leerink Swann Comments on Ionis Pharmaceuticals, Inc.s Q3 2017 Earnings (IONS)Leerink Swann Comments on Ionis Pharmaceuticals, Inc.'s Q3 2017 Earnings (IONS)
www.americanbankingnews.com - October 27 at 6:32 AM
Commit To Buy Ionis Pharmaceuticals At $37, Earn 8.7% Using OptionsCommit To Buy Ionis Pharmaceuticals At $37, Earn 8.7% Using Options
www.nasdaq.com - October 27 at 12:14 AM
Ionis Pharmaceuticals, Inc. (IONS) Downgraded to Hold at Zacks Investment ResearchIonis Pharmaceuticals, Inc. (IONS) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 26 at 11:58 PM

Social Media

Financials

Chart

Ionis Pharmaceuticals (NASDAQ IONS) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.